Duopharma Biotech Bhd Stock Cash And Equivalents
7148 Stock | 1.28 0.01 0.78% |
Duopharma Biotech Bhd fundamentals help investors to digest information that contributes to Duopharma Biotech's financial success or failures. It also enables traders to predict the movement of Duopharma Stock. The fundamental analysis module provides a way to measure Duopharma Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Duopharma Biotech stock.
Duopharma |
Duopharma Biotech Bhd Company Cash And Equivalents Analysis
Duopharma Biotech's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Duopharma Biotech Cash And Equivalents | 31.5 M |
Most of Duopharma Biotech's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Duopharma Biotech Bhd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition |
In accordance with the recently published financial statements, Duopharma Biotech Bhd has 31.5 M in Cash And Equivalents. This is 96.16% lower than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The cash and equivalents for all Malaysia stocks is 98.83% higher than that of the company.
Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
All Next | Launch Module |
Duopharma Fundamentals
Return On Equity | 10.93 | |||
Current Valuation | 1.78 B | |||
Price To Book | 2.32 X | |||
Price To Sales | 2.12 X | |||
Revenue | 639.17 M | |||
EBITDA | 121.38 M | |||
Net Income | 82.98 M | |||
Cash And Equivalents | 31.5 M | |||
Total Debt | 297.8 M | |||
Cash Flow From Operations | 43.2 M | |||
Market Capitalization | 1.56 B | |||
Total Asset | 1.16 B | |||
Z Score | 3.0 | |||
Annual Yield | 0.04 % | |||
Net Asset | 1.16 B | |||
Last Dividend Paid | 0.095 |
About Duopharma Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Duopharma Biotech Bhd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Duopharma Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Duopharma Biotech Bhd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Duopharma Stock
Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.